News
Major health care providers in Latin America implement Devyser’s solutions to improve post-transplant healthcare management
IMSS, Mexico’s largest public health care provider and INP, Mexico’s National Institute of Pediatrics, now use Devyser’s solutions for chimerism monitoring of transplanted patients Stockholm
Cancer doesn’t take a break, neither do we
We’re shipping! While the world focused on Covid-19 testing, cancer did not take a break. We’re so relieved that priorities are now diversifying to include
Devyser at DGTI 2020
Come and visit our virtual booth at DGTI! The 53rd annual meeting in Immunohaematology and Transfusion Medicine is taking place virtually from September 16th to
Devyser welcomes Fredrik Alpsten as new CEO
Devyser welcomes Fredrik Alpsten as new CEO starting September 1st. Ulf Klangby, the former CEO and founder of Devyser, continues as COO and board member
Devyser’s breakthrough NGS product for hereditary breast and ovarian cancer testing now approved for diagnostic use in the EU
Stockholm, 22 July 2020 —Swedish genetic test developer Devyser’s product for hereditary breast and ovarian cancer (HBOC) is now CE labelled and approved for diagnostic
Discover Devyser CFTR 68
https://vimeo.com/434385139/77bd5832b6 Discover Devyser CFTR 68, our latest kit for the analysis of the CFTR gene, capable of detecting up to 68 mutations most commonly associated
Join our Q&A Poster viewings at the ESHG 2020 Virtual Conference!
The Q&A Poster viewing sessions at ESHG 2020 Virtual Conference will highlight two of our products: Devyser RHD, a non-invasive risk screening kit for RhD-negative
World Haemochromatosis Week 2020
From June 1st to June 7th 2020 is World Haemochromatosis Week. Hemochromatosis is characterised by an excess of iron in blood. Causes for the disease
Devyser gears up for global sales of genetic tests — recruits Torbjörn Andersson as Chief Commercial Officer
Stockholm, 26 may 2020 — Devyser welcomes Torbjörn Andersson as Chief Commercial Officer in charge of global sales and marketing of Devyser’s genetic tests. Torbjörn has